AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's ...

Oruka Therapeutics, Inc. ('Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed ...

Respiratory syncytial virus (RSV) causes severe illness in millions of young children each year.1 Globally, it is estimated that over 100 000 children younger than 5 years die each year from RSV; 97% ...

The Centers for Disease Control and Prevention's vaccine advisory committee is set to meet for the first time since Health ...

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product ...

FluMist is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a ...

AstraZeneca's MedImmune has received Food and Drug Administration approval for FluMist, an influenza vaccine that can be administered either by oneself or by a healthcare provider. FluMist, which ...

MedImmune Limited, a unit of AstraZeneca Plc (NASDAQ: AZN), has notified Inovio Pharmaceuticals Inc (NASDAQ: INO) to terminate the DNA cancer vaccine development program agreement. Under the ...

Dublin, July 29, 2020 (GLOBE NEWSWIRE) -- The 'Metastatic Prostate Cancer (MPC) - Pipeline Insight, 2020' drug pipelines has been added to ...

MedImmune has also seen an exodus: Bahija Jallal, David Berman, Koustubh Ranade and, most recently, Mohammed Dar all, a little strangely, ended up at U.K. biotech Immunocore.

MedImmune and Emeryville, California-based 4D Molecular Therapeutics announced the development and commercialization partnership Tuesday, using 4DMT’s vector discovery and engineering ...